List of Excipients in Branded Drug XOSPATA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	FERRIC OXIDE RED	2036-07-01
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	HYDROXYPROPYL CELLULOSE	2036-07-01
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	HYPROMELLOSE	2036-07-01
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE	2036-07-01
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	MAGNESIUM STEARATE	2036-07-01
Astellas Pharma US Inc	XOSPATA	gilteritinib	0469-1425	MANNITOL	2036-07-01

Xospata Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Xospata (gilteritinib fumarate) is a once-daily oral small-molecule tablet approved by the U.S. Food and Drug Administration for adults with relapsed or refractory acute myeloid leukemia (AML) harboring an FLT3 mutation. Its commercial formulation uses conventional tablet excipients rather than a technically complex delivery system. The main opportunities are therefore in generic formulation, excipient substitution, manufacturing efficiency, stability improvement, and differentiated oral delivery rather than in biosimilar development.

The key formulation constraint is clinical exposure. Gilteritinib is administered at 120 mg once daily, and the formulation must preserve reliable absorption in heavily treated AML patients who may have gastrointestinal complications, polypharmacy, hepatic dysfunction, or inconsistent oral intake. Excipients that improve powder flow, tablet robustness, dissolution consistency, and moisture control have the strongest commercial relevance.

What is Xospata and how is it formulated?

Xospata contains gilteritinib fumarate, equivalent to 40 mg of gilteritinib per tablet. The recommended dose is three 40 mg tablets once daily, for a total daily dose of 120 mg. Tablets are swallowed whole and are not intended to be crushed, chewed, or split.[1]

Xospata dosage form and excipient profile

The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Reported excipient or material	Likely technical role
Tablet core	Lactose monohydrate	Diluent and compressibility aid
Tablet core	Microcrystalline cellulose	Filler, dry binder, compactability enhancer
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Hypromellose	Binder and matrix-forming aid
Tablet core	Magnesium stearate	Lubricant
Tablet core	Silicon dioxide	Glidant and moisture or flow-control aid
Film coating	Hypromellose	Film former
Film coating	Talc	Anti-tacking and coating-process aid
Film coating	Titanium dioxide	Opacifier and color modifier
Film coating	Ferric oxide colorants	Tablet identification and appearance

The formulation is consistent with an immediate-release, film-coated tablet manufactured by wet or dry granulation followed by compression and coating. The public label does not identify a modified-release system, lipid formulation, nanocrystal system, or device-enabled delivery platform.[1]

What excipient strategy does Xospata use?

Xospata uses a conventional excipient platform optimized for manufacturability and dose uniformity. The strategy combines lactose and microcrystalline cellulose for bulk and compactability, croscarmellose sodium for rapid tablet breakup, hypromellose for binding, magnesium stearate for lubrication, and silicon dioxide for powder handling.

Why lactose and microcrystalline cellulose matter

Lactose monohydrate provides relatively low-cost tablet mass and supports conventional solid-dose manufacturing. Microcrystalline cellulose improves tablet hardness and compensates for the poorer compactability that can occur with some active pharmaceutical ingredients.

For a 40 mg tablet, the active ingredient represents only part of the tablet mass. The excipient system must deliver:

• Consistent content uniformity across the compression batch.
• Adequate hardness for bottle and shipping operations.
• Rapid disintegration without excessive friability.
• Acceptable dissolution across manufacturing lots.
• Stable performance under long-term storage.

Generic manufacturers can potentially alter the lactose-to-cellulose ratio, replace one filler, or use a co-processed filler-binder. Those changes may reduce granulation steps, improve tablet tensile strength, or lower manufacturing cost, but they must preserve dissolution and bioequivalence performance.

Why croscarmellose sodium is commercially important

Croscarmellose sodium is the principal disintegration-enabling excipient identified in the label. Its performance depends on particle size, degree of substitution, swelling capacity, incorporation method, and compression force.

Potential supplier and formulation opportunities include:

1. High-swelling grades for faster disintegration.
2. Low-fines grades for improved flow and reduced dust.
3. Direct-compression grades for simplified manufacturing.
4. Dual-source grades with comparable functionality for supply security.
5. Excipient systems that preserve dissolution at higher compression force.

A substitute such as sodium starch glycolate or crospovidone could be technically feasible in a generic formulation, but substitution would require comparative dissolution work and likely formulation optimization. A change that improves disintegration in water may not improve dissolution in biorelevant media or under fed conditions.

Why magnesium stearate requires process control

Magnesium stearate is a conventional lubricant, but over-lubrication can reduce tablet tensile strength and slow wetting or dissolution. The risk increases when the formulation uses high shear blending or extended lubrication times.

A generic manufacturer may create value by using:

• Lower lubricant concentration.
• Shorter lubrication time.
• Alternative stearate grades.
• Sodium stearyl fumarate where compatibility and dissolution justify the change.
• Process controls tied to specific surface area and blending energy.

These changes can improve dissolution robustness, but they may also increase ejection force, sticking, or tooling wear. The commercial opportunity is greatest for manufacturers that can control the relationship between lubricant distribution and tablet performance at scale.

What formulation patents protect Xospata?

Xospata is a small-molecule tablet, so the relevant intellectual-property categories are the gilteritinib compound, pharmaceutical compositions, therapeutic uses, salts, crystalline forms, and manufacturing processes. Excipient selection alone is unlikely to provide broad protection unless it is tied to a specific composition, stability result, dissolution profile, or therapeutic advantage.

The original innovator is Astellas Pharma. Gilteritinib was discovered through Astellas' research programs and developed as an FLT3 and AXL tyrosine kinase inhibitor.[2]

Patent categories relevant to excipient suppliers

Excipient and formulation companies should screen claims in five areas:

Patent category	Relevance to excipient strategy
Active-compound patents	May block use of gilteritinib itself during the patent term
Salt or crystal-form patents	May affect selection of gilteritinib fumarate or another solid form
Pharmaceutical-composition patents	May claim excipient classes, ratios, particle size, or dissolution behavior
Method-of-use patents	May affect generic labeling and carved-out indications
Process patents	May cover granulation, blending, compression, coating, or impurity control

The Orange Book should be reviewed for listed patents and expiration dates before commercial development. Orange Book entries can include drug-substance, drug-product, and method-of-use patents, and their practical effect depends on the scope of the claims and the applicant's certification strategy.[3]

Are there broad formulation barriers?

The public dosage form does not indicate a difficult delivery technology. That reduces technical barriers for an ANDA applicant but increases the importance of patent claim construction, bioequivalence, supply reliability, and cost.

A formulation patent would be more commercially meaningful if it claimed a narrow excipient combination that produced a demonstrated result, such as:

• Improved stability against degradation.
• Reduced tablet size.
• Faster dissolution at gastric pH.
• Lower variability under fed conditions.
• Better resistance to humidity.
• Improved handling of a specific gilteritinib solid form.

A generic formulation can sometimes avoid such claims by changing the filler, disintegrant, lubricant, granulation process, or coating system. That strategy requires a claim-by-claim freedom-to-operate review rather than reliance on the label's ingredient list.

When does Xospata lose exclusivity?

Xospata received FDA approval in November 2018. The product also received orphan-drug designation for AML, which generally provides seven years of U.S. marketing exclusivity for the approved orphan indication, subject to statutory exceptions. The orphan exclusivity period would ordinarily extend into November 2025.[1][4]

Patent expiry may extend beyond orphan exclusivity. The controlling date depends on the specific Orange Book-listed patents, patent-term adjustment, patent-term extension, pediatric exclusivity, and any litigation or settlement outcome. A commercial launch assessment should therefore separate:

• FDA regulatory exclusivity.
• Orange Book patent expiry.
• Any pediatric extension.
• Patent litigation timing.
• The scope of the approved generic label.

Xospata exclusivity timeline

Event	Date or status
FDA approval	November 2018
Orphan-drug exclusivity	Generally seven years from approval for the protected indication
Standard generic pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Biosimilar pathway	Not applicable because gilteritinib is a synthetic small molecule
Patent-driven launch date	Depends on listed patents, certifications, litigation, and settlement terms
Market opportunity after orphan exclusivity	Generic entry, authorized generic activity, and formulation substitution

The loss of orphan exclusivity does not automatically mean immediate generic entry. Patent protection and regulatory review timing can remain decisive.

Which companies are challenging Xospata?

Publicly documented challenger activity should be tracked through the FDA Orange Book, Paragraph IV litigation records, ANDA litigation dockets, and company disclosures. A reliable competitive analysis must distinguish between:

• A filed ANDA.
• A Paragraph IV certification.
• A notice letter.
• A patent-infringement complaint.
• A settlement agreement.
• An approved ANDA.
• An actual commercial launch.

The presence of an Orange Book patent does not prove that litigation has occurred. Conversely, the absence of public litigation does not prove that no ANDA has been filed, because regulatory filings and commercial plans may not be fully public.

What is the Paragraph IV risk?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. If the innovator files suit within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to court decisions and statutory exceptions.[5]

For Xospata, likely Paragraph IV targets would include patents covering:

• Gilteritinib compositions.
• Gilteritinib fumarate or another selected solid form.
• Tablets containing specified pharmaceutical compositions.
• Methods of treating FLT3-mutated AML.
• Manufacturing methods that may be difficult to design around.

The commercial value of a Paragraph IV strategy depends on whether the generic applicant can launch after settlement, win an invalidity or non-infringement decision, or accept a later agreed entry date.

What FDA regulatory status applies to Xospata generics?

A generic Xospata product would normally use the ANDA pathway rather than the 505(b)(2) pathway. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

Generic development requirements

A typical development program would address:

• Same active ingredient, strength, dosage form, and route.
• Pharmaceutical equivalence to the 40 mg film-coated tablet.
• Comparative dissolution across approved media.
• In vivo bioequivalence, if required by FDA.
• Impurity and degradation-product control.
• Container-closure compatibility.
• Stability under ICH conditions.
• Manufacturing-process validation.
• Labeling and indication strategy.

A formulation that changes inactive ingredients may still qualify as therapeutically equivalent, but the applicant must demonstrate that the change does not affect safety, efficacy, bioequivalence, or product performance.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are in supply assurance, co-processed excipients, film-coating systems, and formulation services. The product's conventional composition creates a broad supplier base, but oncology products impose higher expectations for quality systems, traceability, and continuity of supply.

Co-processed filler-binders

A co-processed microcrystalline cellulose-lactose or cellulose-based filler-binder could allow a generic manufacturer to:

• Reduce raw-material variability.
• Improve direct-compression performance.
• Remove or reduce wet granulation.
• Improve tablet hardness at lower compression force.
• Reduce production cycle time.

The commercial proposition must be supported by dissolution equivalence and scale-up data. A lower-cost excipient that creates lot-to-lot dissolution variability has limited value in a regulated oncology product.

Disintegrant systems

A higher-performance disintegrant may enable a smaller tablet or faster dissolution. This is relevant because the recommended regimen requires three tablets daily. A supplier that helps reduce tablet weight or improve disintegration may create a meaningful manufacturing or patient-handling advantage.

Film-coating systems

A ready-to-use film-coating system can simplify color matching, reduce coating development time, and improve batch reproducibility. The coating must maintain:

• Visual differentiation of the 40 mg strength.
• Protection from handling abrasion.
• Compatibility with the tablet core.
• Acceptable moisture transmission.
• Regulatory consistency across manufacturing sites.

A coating change is unlikely to produce strong standalone market exclusivity, but it can support a reliable generic launch and reduce technology-transfer risk.

Low-moisture and allergen-sensitive formulations

Lactose-free alternatives could address procurement or patient-preference requirements, although lactose in a tablet is usually present at a quantity below that associated with clinically significant intolerance. Possible alternatives include mannitol, anhydrous dibasic calcium phosphate, starch-derived fillers, or co-processed cellulose systems.

The commercial case is stronger where a manufacturer seeks a differentiated product for institutional formularies, international markets, or patients with excipient restrictions. The substitute must not introduce new risks such as excessive hygroscopicity, poor compactability, or altered dissolution.

Can Xospata support a differentiated formulation?

Yes, but differentiation is more likely to come from dosage convenience or administration flexibility than from a conventional excipient substitution.

Potential differentiated products

Product concept	Commercial rationale	Main development barrier
Higher-strength tablet	Fewer tablets per dose	New strength approval and dose-uniformity work
Orally disintegrating tablet	Easier administration for patients with swallowing difficulty	Taste masking, moisture sensitivity, mechanical strength
Sprinkle or dispersible formulation	Administration flexibility	Stability, dose recovery, and food-effect assessment
Oral suspension	Potential use for patients unable to swallow tablets	Chemical stability, preservative system, dosing accuracy
Smaller film-coated tablet	Improved swallowing and packaging efficiency	Higher drug loading and compression performance
Single-dose blister packaging	Improved adherence and handling	Packaging cost and hospital workflow fit

Any reformulation must account for the approved dosing schedule, the need for accurate 120 mg daily administration, and the potential for serious adverse reactions, including differentiation syndrome, QT prolongation, pancreatitis, and posterior reversible encephalopathy syndrome.[1]

An oral suspension or orally disintegrating tablet could address a real clinical need, but it would require more than excipient substitution. The developer would need to establish dose uniformity, chemical and microbiological stability, administration-device performance, and clinical or bioequivalence comparability.

How does Xospata compare with competing FLT3 therapies?

Xospata competes primarily with other FLT3-directed treatment options and with chemotherapy or transplant strategies rather than with a directly interchangeable tablet.

Product	Active ingredient	Main formulation	Commercial relevance
Xospata	Gilteritinib	40 mg film-coated tablet	Relapsed or refractory FLT3-mutated AML
Rydapt	Midostaurin	Oral capsule	Newly diagnosed FLT3-mutated AML with chemotherapy; systemic mastocytosis
Quizartinib products	Quizartinib	Oral solid dosage forms, depending on market	FLT3-ITD AML in selected treatment settings
Crenolanib	Crenolanib	Development-stage or jurisdiction-dependent	Potential future FLT3 competition

Xospata's excipient opportunity is narrower than its therapeutic market opportunity because its tablet technology is conventional. Its competitive advantages depend more on clinical positioning, physician adoption, mutation testing, dosing, safety management, and access than on proprietary delivery technology.[1][6]

What manufacturing and geographic opportunities exist?

The most practical commercial opportunities are regional generic supply and second-source manufacturing. Gilteritinib products require controlled handling of a potent oncology active ingredient, validated cleaning, containment, and robust analytical methods.

Geographic priorities

Potential markets include the United States, European Union, Japan, China, South Korea, Canada, Australia, and major emerging oncology markets. Each jurisdiction may differ in:

• Patent and supplementary protection certificate status.
• Orphan exclusivity.
• Reference-product requirements.
• Biowaiver or bioequivalence expectations.
• Excipient compendial standards.
• Permitted colorants.
• Local packaging and serialization rules.
• Government procurement requirements.

A formulation developed for the U.S. market may require changes for Europe or Asia because of excipient monographs, colorant restrictions, labeling requirements, or local reference products.

Manufacturing barriers

The principal technical barriers are likely to include:

• Low-dose content uniformity relative to total tablet mass.
• Control of gilteritinib solid-state properties.
• Potent-compound containment.
• Powder segregation during blending and transfer.
• Lubrication sensitivity.
• Moisture and photostability control.
• Analytical detection of low-level impurities.
• Consistent dissolution after scale-up.

These barriers favor contract development and manufacturing organizations with oncology containment infrastructure, rather than excipient vendors operating without formulation support.

How strong is the Xospata patent estate?

The formulation appears technically accessible, but legal risk can remain material because compound, salt, use, and composition patents may extend beyond regulatory exclusivity. Patent strength should be assessed by claim scope, remaining term, prosecution history, validity vulnerabilities, and the availability of a clinically acceptable design-around.

A practical scoring framework is:

Factor	Assessment for commercial planning
Delivery-system complexity	Low to moderate
Excipient substitution feasibility	Moderate to high
Bioequivalence risk	Moderate
Solid-form risk	Potentially material
Method-of-use risk	Material where the label includes patented indications
Manufacturing-process risk	Dependent on process claims
Biosimilar risk	None
Generic competition potential	High after enforceable exclusivity ends

The absence of a complex delivery system does not eliminate patent risk. A generic applicant should separate the drug-substance freedom-to-operate analysis from the tablet formulation and labeling analysis.

Key Takeaways

• Xospata is a 40 mg immediate-release, film-coated gilteritinib tablet administered as three tablets once daily.
• Its excipient system is conventional: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, silicon dioxide, talc, titanium dioxide, and iron-oxide colorants.
• The strongest excipient opportunities involve co-processed filler-binders, high-performance disintegrants, film-coating systems, low-moisture formulations, and second-source supply.
• A generic product would generally use the ANDA pathway. Biosimilar development is not relevant because gilteritinib is a synthetic small molecule.
• Orphan-drug exclusivity began with the November 2018 FDA approval and generally runs for seven years for the protected indication.
• Patent expiry and Paragraph IV litigation remain separate from orphan exclusivity and must be evaluated through current Orange Book and court records.
• Differentiated products such as higher-strength tablets, orally disintegrating tablets, and dispersible formulations could create value, but they require additional bioequivalence, stability, and dose-administration work.
• The most defensible commercial position is a formulation-plus-manufacturing package that reduces cost and supply risk while preserving dissolution and clinical labeling.

FAQs

Does Xospata contain lactose?

Yes. The U.S. label identifies lactose monohydrate as an inactive ingredient in the tablet core.[1]

Can lactose be removed from a generic Xospata tablet?

Potentially. A generic applicant may use another filler or co-processed excipient, provided the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and stability requirements.

Is Xospata a biologic?

No. Xospata contains gilteritinib fumarate, a synthetic small-molecule kinase inhibitor. Generic competition would normally use an ANDA rather than a biosimilar application.

Could an excipient supplier obtain a patent around a Xospata generic?

Possibly, but a patent would need claims directed to a novel and non-obvious composition, process, stability result, dissolution profile, or administration format. A routine substitution of one standard filler for another is unlikely to provide strong standalone protection.

What is the most attractive formulation opportunity for Xospata?

A robust lower-cost tablet using a co-processed filler-binder, optimized disintegrant, and validated low-moisture film-coating system is the most commercially practical opportunity. An orally disintegrating or dispersible product has greater differentiation potential but also substantially higher development and regulatory risk.

References

1. U.S. Food and Drug Administration. (2024). Xospata (gilteritinib) tablets: Prescribing information. Astellas Pharma US, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211349s009lbl.pdf

2. Astellas Pharma Inc. (2024). Annual report 2024. https://www.astellas.com/en/investors/financial-information

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products

5. U.S. Food and Drug Administration. (2018). ANDA submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

6. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Acute myeloid leukemia. National Comprehensive Cancer Network.